CD28 Deficiency Enhances Type I IFN Production by Murine Plasmacytoid Dendritic Cells.
Monica MacalMiguel A TamCharles R HesserJeremy Di DomizioPsylvia LegerMichel GillietElina I ZunigaPublished in: Journal of immunology (Baltimore, Md. : 1950) (2016)
Type I IFNs (IFN-I) are key innate mediators that create a profound antiviral state and orchestrate the activation of almost all immune cells. Plasmacytoid dendritic cells (pDCs) are the most powerful IFN-I-producing cells and play important roles during viral infections, cancer, and autoimmune diseases. By comparing gene expression profiles of murine pDCs and conventional DCs, we found that CD28, a prototypic T cell stimulatory receptor, was highly expressed in pDCs. Strikingly, CD28 acted as a negative regulator of pDC IFN-I production upon TLR stimulation but did not affect pDC survival or maturation. Importantly, cell-intrinsic CD28 expression restrained pDC (and systemic) IFN-I production during in vivo RNA and DNA viral infections, limiting antiviral responses and enhancing viral growth early after exposure. Finally, CD28 also downregulated IFN-I response upon skin injury. Our study identified a new pDC regulatory mechanism by which the same CD28 molecule that promotes stimulation in most cells that express it is co-opted to negatively regulate pDC IFN-I production and limit innate responses.
Keyphrases
- dendritic cells
- immune response
- regulatory t cells
- sars cov
- nk cells
- induced apoptosis
- toll like receptor
- transcription factor
- squamous cell carcinoma
- inflammatory response
- stem cells
- poor prognosis
- cell cycle arrest
- binding protein
- single molecule
- gene expression
- cell therapy
- mesenchymal stem cells
- nuclear factor
- squamous cell
- pi k akt